Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.
Jain
Mukta
M
Oxford Children's Hospital, The John Radcliffe, Headington, UK.
Thomson
Anne H
AH
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000276:immunology; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000517:prevention & control; D000069455:Palivizumab; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D018410:Pneumonia, Bacterial / Q000517:prevention & control; D011024:Pneumonia, Viral / Q000517:prevention & control; D013296:Streptococcus pneumoniae / Q000276:immunology; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines; D000069455:Palivizumab